Four pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Omeros Corporation (OMER) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Omeros is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. Shares of OMER have increased 58% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of OMER stock.
This week, Watson Pharmaceuticals (WPI) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Questcor Pharmaceuticals, Inc. (QCOR) earns an A this week, jumping up from last week’s grade of B. Questcor Pharmaceuticals develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. For more information, get Portfolio Grader’s complete analysis of QCOR stock.
Corcept Therapeutics Incorporated. (CORT) boosts its rating from a C to a B this week. Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. For more information, get Portfolio Grader’s complete analysis of CORT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.